ASCO GI 2023 | Optimizing HCC treatment with predicative biomarkers

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, describes current areas of unmet need in hepatocellular carcinoma. Despite the advent of numerous treatment regimens such as atezolizumab with bevacizumab and durvalumab with tremelimumab, a number patients will progress on these therapies. Therefore, predicative biomarkers are important to find patients who will benefit from these immunotherapies the most. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.